← ANALYST RATINGS · TIPRANKS
Tenax Therapeutics (TENX): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy4 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $9.62, the highest $35.00, the lowest $4.00. The average is +607.7% from the last price of $1.36.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Sell | +10.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Sell | +10.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Sell | +10.3% | Downgrade | 14.10.26on TipRanks 06:05 | — | |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $4.00 | Buy | +194.1% | Reiterated | 09.10.26on TipRanks Oct 12 05:20 | −0.1%next day −2.1% · 5 days −25.3% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 → $2.00+33.3% | Sell | +47.1% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 → $2.00+33.3% | Sell | +47.1% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 | Sell | +47.1% | Downgrade | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 | Hold | +47.1% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Sell | +10.3% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 | Hold | +47.1% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 | Sell | +10.3% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 | Hold | +47.1% | Upgrade | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 | Hold | +47.1% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $14.00 | Buy | +929.4% | Reiterated | 15.09.26on TipRanks 07:45 | −1.2%next day −0.1% · 5 days +3.6% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $35.00 | Buy | +2,473.5% | Reiterated | 09.09.26on TipRanks Sep 10 09:16 | +8.0%next day −7.9% · 5 days −13.5% | ↗ |
| Name not given | — | $4.00 | Buy | +194.1% | Reiterated | 31.08.26on TipRanks Sep 1 08:35 | −13.3%next day −1.5% · 5 days +7.8% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Hold | — | Reiterated | 31.08.26on TipRanks 07:15 | −13.3%next day −1.5% · 5 days +7.8% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | — | Hold | — | Downgrade | 31.08.26on TipRanks 06:20 | −13.3%next day −1.5% · 5 days +7.8% | ↗ |
| Name not given | — | $27.00 → $5.00−81.5% | Hold | +267.6% | Downgrade | 11.08.26on TipRanks Aug 13 10:20 | +18.1%next day +5.9% · 5 days +5.3% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $26.00 → $4.00−84.6% | Buy | +194.1% | Reiterated | 11.08.26on TipRanks 06:20 | +18.1%next day +5.9% · 5 days +5.3% | ↗ |
| Jonathan Aschoff★★★★★★★★★★#12373 · hits 29% · avg −21.0% | Roth MKM | $30.00 → $5.00−83.3% | Buy | +267.6% | Reiterated | 10.08.26on TipRanks Aug 11 02:05 | −89.7%next day +18.1% · 5 days +24.4% | ↗ |
| Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% | LifeSci Capital | $35.00 → $5.00−85.7% | Buy | +267.6% | Reiterated | 10.08.26on TipRanks 18:30 | +18.1%next day +5.9% · 5 days +5.3% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $39.00 → $5.00−87.2% | Hold | +267.6% | Downgrade | 10.08.26on TipRanks 16:30 | +18.1%next day +5.9% · 5 days +5.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Tenax Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.62 at a price of $1.89 (+409.3%); now: $9.62 at $1.36 (+607.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 15 | 21 | 18 | 13 |
| Buy | 6 | 5 | 4 | 3 | 3 | 0 |
| Hold | 0 | 0 | 0 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.36 (from $-0.39 to $-0.33). Last quarter: $-0.35.
Best top-analyst consensus in the sector · Healthcare
About Tenax Therapeutics
- CEO: Christopher T. Giordano
- Employees: 15
- 101 Glen Lennox Drive, Chapel Hill, NC, 27517, US
- www.tenaxthera.com
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗